Insulet Co. (NASDAQ:PODD) Stock Position Decreased by Chicago Capital LLC

Chicago Capital LLC cut its stake in Insulet Co. (NASDAQ:PODD) by 2.6% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 162,877 shares of the medical instruments supplier’s stock after selling 4,361 shares during the period. Chicago Capital LLC’s holdings in Insulet were worth $32,869,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in Insulet by 1.1% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock worth $1,264,000 after purchasing an additional 66 shares in the last quarter. UMB Bank n.a. grew its holdings in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 81 shares during the period. Moody National Bank Trust Division raised its position in Insulet by 2.6% in the first quarter. Moody National Bank Trust Division now owns 3,439 shares of the medical instruments supplier’s stock worth $589,000 after acquiring an additional 87 shares in the last quarter. Motley Fool Asset Management LLC lifted its holdings in Insulet by 7.1% in the 1st quarter. Motley Fool Asset Management LLC now owns 1,397 shares of the medical instruments supplier’s stock valued at $239,000 after acquiring an additional 93 shares during the last quarter. Finally, State of Michigan Retirement System boosted its position in shares of Insulet by 0.5% during the 2nd quarter. State of Michigan Retirement System now owns 19,200 shares of the medical instruments supplier’s stock valued at $3,875,000 after purchasing an additional 100 shares in the last quarter.

Insider Transactions at Insulet

In other news, SVP Mark N. Field sold 2,131 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $190.43, for a total value of $405,806.33. Following the sale, the senior vice president now owns 14,375 shares in the company, valued at approximately $2,737,431.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Insulet news, Director Timothy J. Scannell sold 7,000 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the transaction, the director now directly owns 35,586 shares in the company, valued at approximately $6,779,488.86. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Mark N. Field sold 2,131 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $190.43, for a total value of $405,806.33. Following the completion of the transaction, the senior vice president now directly owns 14,375 shares in the company, valued at approximately $2,737,431.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,631 shares of company stock valued at $2,039,316. Corporate insiders own 0.47% of the company’s stock.

Insulet Stock Performance

Insulet stock traded down $1.36 on Friday, reaching $214.75. 559,605 shares of the stock were exchanged, compared to its average volume of 835,722. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36. The firm has a fifty day moving average price of $196.15 and a two-hundred day moving average price of $184.32. The stock has a market cap of $15.04 billion, a PE ratio of 65.08, a PEG ratio of 3.79 and a beta of 1.21. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $223.56.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The company had revenue of $488.50 million for the quarter, compared to analyst estimates of $488.00 million. During the same quarter in the previous year, the company earned $0.38 earnings per share. Insulet’s revenue for the quarter was up 23.2% compared to the same quarter last year. Sell-side analysts anticipate that Insulet Co. will post 3.04 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PODD. BTIG Research cut their target price on Insulet from $270.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Redburn Atlantic initiated coverage on shares of Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 price objective for the company. Barclays raised their target price on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. OTR Global reaffirmed a “mixed” rating on shares of Insulet in a research note on Monday, June 10th. Finally, UBS Group increased their price objective on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $225.29.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.